Driven by the idiopathic pulmonary fibrosis market, Boehringer Ingelheim’s Ofev finally hit blockbuster sales in 2018. An FDA nod in a rare lung disease, Ofev is targeting even more small indications to add to its portfolio.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,